It was demonstrated that targeted inhibition of mitochondrial Hsp90 with Gamitrinib reversed pulmonary vascular remodeling and improved cardiac output in two PAH models without noticeable toxicity (Boucherat et al., 2018). The gene discussed is HSP90AB1; the disease is pulmonary arterial hypertension.